Please select the option that best describes you:
What are your top takeaways in Gyn Cancers from ASCO 2024?
Answer from: Radiation Oncologist at Academic Institution
ASCO 2024 was a quiet year for the gynecological cancer community without too many fireworks. For the radiation oncologists, there were very few positive studies. I will highlight a few important ones
1. Oral abstract #5504 was on “Adjuvant chemotherapy following concurrent chemoradiation (CR...
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
NRG oncology/RTOG 0724/GOG-0724 - NRG study for adjuvant chemotherapy after concurrent chemo RT for high-risk post operative cervical cancer showed no difference in recurrence pattern and DFS with the addition of chemotherapy. As expected, grade 3-4 acute complications were higher with the addition ...
Answer from: at Academic Institution
Numerous important gynecologic oncology studies were presented at ASCO 2024. The following three are clinically important and/or practice-changing.
CARACO Trial (NCT01218490) - Omission of Lymphadenectomy in Advanced Epithelial Ovarian Cancer
CARACO is a large (n=450) multicenter randomized phase ...